Cholestatic Liver Diseases: New Strategies for Prevention and Treatment of Hepatobiliary and Cholestatic Liver

Preface. Section I: Mechanisms of Bile Formation and Cholestasis. 1. Histopathology of cholestasis; W.J. Desmet. 2. Mechanisms of bile formation; J.L. Boyer. 3. The enterohepatic circulation of bile acids in mammals; A.F. Hofmann. 4. The relationship between hepatobiliary transport and cholestatic properties of lithocholic acid conjugates in rats; F. Kuipers, R. Havinga, R. van der Meer, N.R. Koopen, R.J. Vonk. 5. Profiles of steroids and bile acids in plasma of patients with intrahepatic cholestasis of pregnancy -- effect of ursodeoxycholic acid therapy; L.J. Meng, H. Reyes, J. Palma, I. Hernandez, J. Ribalta, J. Sjövall. Section II: Hepatocellular Transport and Mechanisms of Cholestasis. 6. Bilirubin metabolism in cholestasis; N. Blanckaert. 7. Molecular mechanisms of bile acid transport in hepatocytes; P.J. Meier. 8. Pathways of bile acid conjugation; S. Matern, H.-U. Marschall, H. Heinemann, C. Gartung, H. Wietholtz, H. Matern, J. Sjövall. 9. Characterization of the mechanism of glucuronidation using photoaffinity labelling; A. Radominska, R.R. Drake, S. Treat, R. Lester. 10. Drugs, chemicals and cellular mechanisms of cholestasis; I.M. Arias, Z. Gatmaitan, J.F. Dufour, M. St.Pierre, L. Epstein, M. Che, Y. Matsuda, C. Leveille-Webster. 11. Transport of taurine conjugates of 7alpha-hydroxy-3-oxo-4-cholenoic acid and 3beta, 7alpha-dihydroxy-5-cholenoic acid in rat liver plasma membrane vesicles; B. Steiger, J. Zhang, B. O'Neill, J. Sjovall, P.J. Meier. Section III: Mechanisms of Gallstone Formation and Cholestasis. 12. Biliary lipid secretion and cholesterol transport; M.C. Carey. 13. Control of biliary lipid secretion. Studies in the mdr2 P-glycoprotein knock-out mouse; A.K. Groen, R. Ottendorf, M.J.A. van Wijland, J.J.M. Smit, A.H. Schinkel, R.P.J. Oude Elferink. 14. The role of gallbladder motility in the pathogenesis of cholesterol gallstones; M.F.J. Stolk, P. Portincasa, K.J. van Erpecum, G.P. van Berge Henegouwen. 15. Cholesterol crystal morphology is changed by a unique subgroup of lectin bound biliary proteins; N. Busch, F. Lammert, S. Matern. 16. Cholesterol crystal nucleation in bile: role of protein hydrophobicity; H.A. Ahmed, M.L. Petroni, M. Abu-Hamdiyyah, R.P. Jazraw, T.C. Northfield. 17. Nutrition associated cholestasis; P.B. Soeters. 18. Cholestatic liver diseases in children; C. Colombo. 19. Inborn errors of bile acid synthesis: a new category of metabolic liver disease; K.D.R. Setchell. Section IV: Ductopenic Diseases: Pathophysiology and Treatment. 20. Pathology of ductopenia with a particular reference to primary biliary cirrhosis and liver allograft rejection; B.C. Portmann. 21. Immunological aspects of cholestatic liver disease; M.F. Bassendine, D.E.J. Jones, M.P. Leon, J. Kiby, J.M. Palmer, S.J. Yeaman, A.G. Diamond. 22. Epidemiological and clinical features of primary biliary cirrhosis and primary sclerosing cholangitis; R.H. Wiesner. 23. Mechanisms of action of ursodeoxycholic acid in cholestasis; R. Poupon, R.E. Poupon. 24. Cytoprotection by ursodeoxycholic acid; U. Leuschner, S. Guldutuna, S. Bhatti, P. Sipos, T. You, G. Zimmer. 25. Methionine enkephalin and aminopeptidase-M activity in blood in children with cholestasis before and after treatment with ursodeoxycholic acid; R.M. Janas, J. Tretter, K. Warnawin, J. Pawlowska, J. Rujner, J. Socha. 26. Treatment with ursodeoxycholic acid, as monotherapy and in combination with other agents, in primary biliary cirrhosis; H.R. van Buuren, F.H.J. Wolfhagen, S.W. Schalm. 27. Methotrexate alone or in combination with ursodeoxycholic acid as possible treatment in primary biliary cirrhosis; W. Van Steenbergen, R. Sciot, P. Van Eycken, V. Desmet, J. Fevery. 28. Colchicine treatment and prognostic value of cholangiography in primary sclerosing cholangitis; R. Olsson, U. Broome, A. Danielsson, I. Hagerstrand, G. Jarnerot, L. Loof, H. Prytz, B.-O. Ryden, S. Wallerstedt, M. Asztely. 29. Treatment of primary sclerosing cholangitis; R.W. Chapman. 30. Treatment of primary sclerosing cholangitis with ursodeoxycholic acid; A. Stiehl. 31. Liver transplantation for cholestatic liver diseases; J.B. Otte, J. Lerut. 32. Large bile duct strictures in primary sclerosing cholangitis patients developing ductopenic rejection after liver transplantation; does this represent ...; B. van Hoek, R.H. Wiesner, L. Sanchez-Urdazpal, J. Ludwig, R.A.F. Krom. Section V: Gallbladder and Bile Duct Stone: Epidemiology and Treatment. 33. Epidemiology of gallstone disease; E. Road, D. Festi, S. Sottili, A. Sangermano, A. Colecchia, M. Orsini, the MICOL Group. 34. Duodenal diverticula are associated with pancreatic, biliary and intestinal anomalies; J.P. van Basten, P. Caenepeel, R. Zeijen, R.W. Stockbrügger. <35. Pathogenesis of gallbladder stone and strategies for their prevention; R.H. Dowling, S.H. Hussaini, S. Pereira, J.A.H. Wass, G.M. Murphy. 36. Ultrasonographic study of gallbladder and gastric dynamics in obese people after oral cholestyramine; P. Portincasa, A. Di Ciaula, V. Palmieri, G.P. van Berge Henegouwen, G. Palasciano. 37. Gallbladder and bile duct stone. Endoscopic treatment; P.B. Cotton. 38. Extracorporeal shock-wave treatment of gallbladder and bile duct stones; G. Paumgartner. 39. Implications of laparoscopic cholecystectomy; O.T. Terpstra. Index.